Is inflammation important in early PPMS? a longitudinal MRI study
暂无分享,去创建一个
A J Thompson | J Sastre-Garriga | A. Thompson | J. Sastre-Garriga | G. Ingle | D H Miller | G T Ingle | A. Thompson | D. Miller | D. Miller | D. Miller | A. Thompson
[1] David H. Miller,et al. Primary-progressive multiple sclerosis , 2007, The Lancet Neurology.
[2] D. Li,et al. Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions , 2003, Multiple sclerosis.
[3] J. Wolinsky. The diagnosis of primary progressive multiple sclerosis , 2003, Journal of the Neurological Sciences.
[4] D. Miller,et al. Interferon β-1a in primary progressive MS , 2003, Neurology.
[5] D. Miller,et al. Triple dose gadolinium enhanced MRI of the brain and spinal cord in early relapsing remitting multiple sclerosis is predictive of future relapses , 2002 .
[6] David J. Brooks,et al. The genetic basis and phenotypic variability in early onset parkinsonism , 2002 .
[7] C. Good,et al. A modified protocol to improve the detection of enhancing brain and spinal cord leasions in multiple sclerosis , 2001, Journal of Neurology.
[8] A J Thompson,et al. Diagnostic criteria for primary progressive multiple sclerosis: A position paper , 2000, Annals of neurology.
[9] Nick C Fox,et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS , 2000, Neurology.
[10] J. Whitaker,et al. Clinical and laboratory features of primary progressive and secondary progressive MS , 1999, Neurology.
[11] R. Rudick. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics. , 1999, Archives of neurology.
[12] Stephen M. Rao,et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.
[13] M. Horsfield,et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. , 1998, Brain : a journal of neurology.
[14] F. Barkhof,et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. , 1998, AJNR. American journal of neuroradiology.
[15] Hans Lassmann,et al. Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology , 1997, Annals of neurology.
[16] G J Barker,et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. , 1997, Brain : a journal of neurology.
[17] A J Thompson,et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.
[18] A. Thompson,et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. , 1996, Brain : a journal of neurology.
[19] G. Barker,et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. , 1996, Journal of neurology, neurosurgery, and psychiatry.
[20] M. Filippi,et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. , 1995 .
[21] A J Thompson,et al. A comparison of the pathology of primary and secondary progressive multiple sclerosis. , 1994, Brain : a journal of neurology.
[22] J. Taubenberger,et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.
[23] A. Thompson,et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis , 1991, Annals of neurology.
[24] B E Kendall,et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. , 1988, Brain : a journal of neurology.
[25] S W Atlas,et al. Multiple sclerosis: gadolinium enhancement in MR imaging. , 1986, Radiology.
[26] J. Bull,et al. Institute of Neurology , 1966 .
[27] D. Chard,et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. , 2003, Neurology.
[28] R. He,et al. Overview of Treatment Trials: Early Baseline Clinical and MRI Data of the PROMiSe Trial , 2002 .